{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:15:25Z","timestamp":1783124125681,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00228-025-03875-x","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T17:02:54Z","timestamp":1753376574000},"page":"1439-1449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["External validation of population pharmacokinetic models of oxcarbazepine active metabolite in Chinese children with epilepsy"],"prefix":"10.1007","volume":"81","author":[{"given":"Ruoyun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"3875_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/b978-0-444-64148-9.00011-9","volume":"174","author":"F Bastos","year":"2020","unstructured":"Bastos F, Cross JH (2020) Epilepsy. Handb Clin Neurol 174:137\u2013158. https:\/\/doi.org\/10.1016\/b978-0-444-64148-9.00011-9","journal-title":"Handb Clin Neurol"},{"issue":"9509","key":"3875_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s0140-6736(06)68182-8","volume":"367","author":"R Guerrini","year":"2006","unstructured":"Guerrini R (2006) Epilepsy in children. Lancet 367(9509):499\u2013524. https:\/\/doi.org\/10.1016\/s0140-6736(06)68182-8","journal-title":"Lancet"},{"issue":"1","key":"3875_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cppeds.2014.12.002","volume":"45","author":"A Tolaymat","year":"2015","unstructured":"Tolaymat A, Nayak A, Geyer JD, Geyer SK, Carney PR (2015) Diagnosis and management of childhood epilepsy. Curr Probl Pediatr Adolesc Health Care 45(1):3\u201317. https:\/\/doi.org\/10.1016\/j.cppeds.2014.12.002","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"1","key":"3875_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1517\/14656566.3.1.59","volume":"3","author":"A Beydoun","year":"2002","unstructured":"Beydoun A, Kutluay E (2002) Oxcarbazepine. Expert Opin Pharmacother 3(1):59\u201371. https:\/\/doi.org\/10.1517\/14656566.3.1.59","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"3875_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1212\/con.0000000000001104","volume":"28","author":"BW Abou-Khalil","year":"2022","unstructured":"Abou-Khalil BW (2022) Update on antiseizure medications 2022. Continuum (Minneap Minn) 28(2):500\u2013535. https:\/\/doi.org\/10.1212\/con.0000000000001104","journal-title":"Continuum (Minneap Minn)"},{"issue":"Suppl 5","key":"3875_CR6","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1111\/j.1528-1157.1999.tb00918.x","volume":"40","author":"ES Tecoma","year":"1999","unstructured":"Tecoma ES (1999) Oxcarbazepine. Epilepsia 40(Suppl 5):S37-46. https:\/\/doi.org\/10.1111\/j.1528-1157.1999.tb00918.x","journal-title":"Epilepsia"},{"issue":"4","key":"3875_CR7","first-page":"181","volume":"36","author":"G Emilien","year":"1998","unstructured":"Emilien G, Maloteaux JM (1998) Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities. Int J Clin Pharmacol Ther 36(4):181\u2013194","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"3875_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/17512433.2021.1917377","volume":"14","author":"Y-T Chen","year":"2021","unstructured":"Chen Y-T, Wang C-Y, Yin Y-W, Li Z-R, Lin W-W, Zhu M, Jiao Z (2021) Population pharmacokinetics of oxcarbazepine: a systematic review. Expert Rev Clin Pharmacol 14(7):853\u2013864. https:\/\/doi.org\/10.1080\/17512433.2021.1917377","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"3875_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pediatrneurol.2005.05.011","volume":"33","author":"RS Northam","year":"2005","unstructured":"Northam RS, Hernandez AW, Litzinger MJ, Minecan DN, Glauser TA, Mangat S, Zheng C, Souppart C, Sturm Y (2005) Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol 33(5):337\u2013344. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2005.05.011","journal-title":"Pediatr Neurol"},{"issue":"10","key":"3875_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/aps.2014.76","volume":"35","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhang HN, Niu CH, Gao P, Chen YJ, Peng J, Liu MC, Xu H (2014) Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin 35(10):1342\u20131350. https:\/\/doi.org\/10.1038\/aps.2014.76","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"3875_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.5414\/cp202078","volume":"52","author":"J Peng","year":"2014","unstructured":"Peng J, Zhang HN, Liu ZS, Xu H, Wang Y (2014) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. Int J Clin Pharmacol Ther 52(8):684\u2013692. https:\/\/doi.org\/10.5414\/cp202078","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"3875_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.dmpk.2014.12.002","volume":"30","author":"I Sugiyama","year":"2015","unstructured":"Sugiyama I, Bouillon T, Yamaguchi M, Suzuki H, Hirota T, Fink M (2015) Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities. Drug Metab Pharmacokinet 30(2):160\u2013167. https:\/\/doi.org\/10.1016\/j.dmpk.2014.12.002","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"3875_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/jcpt.12792","volume":"44","author":"CY Chen","year":"2019","unstructured":"Chen CY, Zhou Y, Cui YM, Yang T, Zhao X, Wu Y (2019) Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Ther 44(2):300\u2013311. https:\/\/doi.org\/10.1111\/jcpt.12792","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"3875_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00228-018-2600-8","volume":"75","author":"WW Lin","year":"2019","unstructured":"Lin WW, Li XW, Jiao Z, Zhang J, Rao X, Zeng DY, Lin XH, Wang CL (2019) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. Eur J Clin Pharmacol 75(3):381\u2013392. https:\/\/doi.org\/10.1007\/s00228-018-2600-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3875_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/bcpt.14000","volume":"134","author":"W Wu","year":"2024","unstructured":"Wu W, Yang WS, Xu XY, Ge XL, Lu J, Wang GF, Wang Y, Li ZP (2024) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: model-based dose optimization. Basic Clin Pharmacol Toxicol 134(5):712\u2013726. https:\/\/doi.org\/10.1111\/bcpt.14000","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"3875_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","volume":"42","author":"TW May","year":"2003","unstructured":"May TW, Korn-Merker E, Rambeck B (2003) Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 42(12):1023\u20131042. https:\/\/doi.org\/10.2165\/00003088-200342120-00002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3875_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","volume":"24","author":"G Flesch","year":"2004","unstructured":"Flesch G (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24(4):185\u2013203. https:\/\/doi.org\/10.2165\/00044011-200424040-00001","journal-title":"Clin Drug Investig"},{"issue":"3","key":"3875_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","volume":"16","author":"C Johannessen Landmark","year":"2020","unstructured":"Johannessen Landmark C, Johannessen SI, Patsalos PN (2020) Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol 16(3):227\u2013238. https:\/\/doi.org\/10.1080\/17425255.2020.1724956","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1\u201302","key":"3875_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gr\u00fcnder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, M\u00f6ssner R, M\u00fcller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1\u201302):9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"3875_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ (2018) Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit 40(5):526\u2013548. https:\/\/doi.org\/10.1097\/FTD.0000000000000546","journal-title":"Ther Drug Monit"},{"issue":"7","key":"3875_CR21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49(7):1239\u20131276. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x","journal-title":"Epilepsia"},{"issue":"3","key":"3875_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s13318-022-00756-x","volume":"47","author":"AA Al-Qurain","year":"2022","unstructured":"Al-Qurain AA, Upton RN, Tadros R, Roberts MS, Wiese MD (2022) Population pharmacokinetic model for tramadol and O-desmethyltramadol in older patients. Eur J Drug Metab Pharmacokinet 47(3):387\u2013402. https:\/\/doi.org\/10.1007\/s13318-022-00756-x","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10","key":"3875_CR23","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1007\/s00431-023-05092-z","volume":"182","author":"X Li","year":"2023","unstructured":"Li X, Wei S, Wu H, Zhang Q, Zhao Z, Mei S, Feng W, Wu Y (2023) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. Eur J Pediatr 182(10):4509\u20134521. https:\/\/doi.org\/10.1007\/s00431-023-05092-z","journal-title":"Eur J Pediatr"},{"key":"3875_CR24","doi-asserted-by":"crossref","unstructured":"Patsalos PN (2022) Oxcarbazepine. In: Patsalos PN (ed) Antiseizure medication interactions: a clinical guide. Springer International Publishing, pp 107\u2013110","DOI":"10.1007\/978-3-030-82790-8_19"},{"issue":"12","key":"3875_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00228-021-03193-y","volume":"77","author":"YQ Li","year":"2021","unstructured":"Li YQ, Chen KF, Ding JJ, Tan HY, Yang N, Lin YQ, Wu CF, Xie YL, Yang GP, Liu JJ, Pei Q (2021) External evaluation of published population pharmacokinetic models of polymyxin B. Eur J Clin Pharmacol 77(12):1909\u20131917. https:\/\/doi.org\/10.1007\/s00228-021-03193-y","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3875_CR26","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00228-022-03359-2","volume":"78","author":"W Huang","year":"2022","unstructured":"Huang W, Zheng Y, Huang H, Cheng Y, Liu M, Chaphekar N, Wu X (2022) External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy. Eur J Clin Pharmacol 78(9):1447\u20131457. https:\/\/doi.org\/10.1007\/s00228-022-03359-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3875_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154\u2013166. https:\/\/doi.org\/10.1016\/j.cmpb.2007.12.002","journal-title":"Comput Methods Programs Biomed"},{"issue":"12","key":"3875_CR28","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/psp4.12720","volume":"10","author":"PO Hanafin","year":"2021","unstructured":"Hanafin PO, Nation RL, Scheetz MH, Zavascki AP, Sandri AM, Kwa AL, Cherng BPZ, Kubin CJ, Yin MT, Wang J, Li J, Kaye KS, Rao GG (2021) Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT Pharmacometrics Syst Pharmacol 10(12):1525\u20131537. https:\/\/doi.org\/10.1002\/psp4.12720","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"3875_CR29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00228-023-03511-6","volume":"79","author":"S Wei","year":"2023","unstructured":"Wei S, Chen J, Zhao Z, Mei S (2023) External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients. Eur J Clin Pharmacol 79(8):1031\u20131042. https:\/\/doi.org\/10.1007\/s00228-023-03511-6","journal-title":"Eur J Clin Pharmacol"},{"key":"3875_CR30","doi-asserted-by":"publisher","unstructured":"Wang S, Yin Q, Yang M, Cheng Z, Xie F (2023) External evaluation of population pharmacokinetic models of methotrexate for model-informed precision dosing in pediatric patients with acute lymphoid leukemia. Pharmaceutics 15(2). https:\/\/doi.org\/10.3390\/pharmaceutics15020569","DOI":"10.3390\/pharmaceutics15020569"},{"issue":"5","key":"3875_CR31","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/17512433.2022.2075849","volume":"15","author":"Y-N Zang","year":"2022","unstructured":"Zang Y-N, Guo W, Dong F, Li A-N, de Leon J, Ruan C-J (2022) Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder. Expert Rev Clin Pharmacol 15(5):621\u2013635. https:\/\/doi.org\/10.1080\/17512433.2022.2075849","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"3875_CR32","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1111\/j.1528-1167.2010.02771.x","volume":"51","author":"I Wegner","year":"2010","unstructured":"Wegner I, Edelbroek P, de Haan GJ, Lindhout D, Sander JW (2010) Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia 51(12):2500\u20132502. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02771.x","journal-title":"Epilepsia"},{"issue":"9","key":"3875_CR33","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo Y-A, Anderson B (2013) A pharmacokinetic standard for babies and adults. J Pharm Sci 102(9):2941\u20132952. https:\/\/doi.org\/10.1002\/jps.23574","journal-title":"J Pharm Sci"},{"issue":"5","key":"3875_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NH Holford","year":"1996","unstructured":"Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30(5):329\u2013332. https:\/\/doi.org\/10.2165\/00003088-199630050-00001","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"3875_CR35","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1111\/bcp.13392","volume":"83","author":"C Rodrigues","year":"2017","unstructured":"Rodrigues C, Chiron C, Rey E, Dulac O, Comets E, Pons G, Jullien V (2017) Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. Br J Clin Pharmacol 83(12):2695\u20132708. https:\/\/doi.org\/10.1111\/bcp.13392","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03875-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03875-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03875-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:36:44Z","timestamp":1758091004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03875-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3875"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03875-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration, and the ethical standards of the institutional and\/or national research committee and its later amendments or comparable ethical standards, and approved by the Ethics Committee of Beijing Children\u2019s Hospital (ID: 2019-k-150).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}